Patents Assigned to Impel NeuroPharma Inc.
  • Patent number: 11278492
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 22, 2022
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
  • Patent number: 11266799
    Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 8, 2022
    Assignee: Impel Neuropharma, Inc.
    Inventors: Christopher Fuller, John D. Hoekman, Craig Kohring
  • Patent number: 11191910
    Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 7, 2021
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
  • Patent number: 11185497
    Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 30, 2021
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Stephen B. Shrewsbury, Scott Youmans, Christopher Fuller
  • Patent number: 11007332
    Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 18, 2021
    Assignee: IMPEL NEUROPHARMA, INC.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
  • Patent number: 10940278
    Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 9, 2021
    Assignee: IMPEL NEUROPHARMA, INC.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
  • Patent number: 10537692
    Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 21, 2020
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
  • Patent number: 10507295
    Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 17, 2019
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
  • Patent number: 9919117
    Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 20, 2018
    Assignee: IMPEL NEUROPHARMA INC.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
  • Patent number: 9550036
    Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: January 24, 2017
    Assignee: Impel NeuroPharma Inc.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
  • Publication number: 20160101245
    Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
    Type: Application
    Filed: April 28, 2014
    Publication date: April 14, 2016
    Applicant: IMPEL NEUROPHARMA INC.
    Inventors: John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
  • Publication number: 20140083424
    Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 27, 2014
    Applicant: Impel NeuroPharma Inc.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
  • Publication number: 20140014104
    Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 16, 2014
    Applicant: Impel NeuroPharma Inc.
    Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J.Y. Ho